应重视门静脉高压症的病因诊断及规范治疗

赵连晖; 贾继东

doi:10.3969/j.issn.1001-5256.2019.01.001

应重视门静脉高压症的病因诊断及规范治疗

DOI: 10.3969/j.issn.1001-5256.2019.01.001

首都医科大学附属北京友谊医院肝病中心

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1677
- HTML全文浏览量: 46
- PDF下载量: 532
- 被引次数: 0
出版历程
- 收稿日期: 2018-12-19
- 出版日期: 2019-01-20

Etiological diagnosis and standard treatment of portal hypertension should be taken seriously

Liver Research Center, Beijing Friendship Hospital, Capital Medical University

摘要

摘要: 门静脉高压症是由门静脉系统阻力/血流增加或肝静脉系统回流受阻所导致的门静脉压力异常升高,常表现为脾大、脾功能亢进、食管胃静脉曲张及破裂出血、腹水及肝性脑病等。肝硬化所引起的窦性门静脉高压症临床最为常见,通常伴有肝脏合成功能障碍。而肝外、肝内门静脉系统异常所致的肝(窦)前门静脉高压,以及肝内、肝外肝静脉系统回流受阻所致的肝(窦)后性门静脉高压,多无明显肝脏合成功能障碍。可首先根据临床症状、体征及血液学指标判断有无门静脉高压症,再通过影像学、肝静脉压力梯度及组织病理学检查明确其类型和病因。应在积极治疗原发病的基础上,采取非选择性β受体阻断剂、内镜、介入或手术治疗,以防治门静脉高压症的并发症。
- 高血压,门静脉 /
- 诊断 /
- 治疗 /
- 述评
Abstract: Portal hypertension (PH) referes to an abnormal increase in portal venous pressure due to increased resistance and/or blood flow of the portal vein or backflow obstruction of the hepatic veins and often manifests as splenomegaly, hypersplenism, gastroesophageal varices and bleeding, ascites, and hepatic encephalopathy.Liver synthetic dysfunction is often seen in sinusoidal PH caused by liver cirrhosis, while it is less often seen in pre-hepatic/pre-sinusoidal PH due to abnormalities in the extrahepatic and intrahepatic portal veins or posthepatic/post-sinusoidal PH due to backflow obstruction of the extrahepatic and intrahepatic hepatic veins.The presence or absence of PH can be determined by clinical symptoms, signs, and hematological parameters, and type and etiology can be clarified by imaging examinations, hepatic venous pressure gradient, and histopathological features.In addition to the active treatment of primary diseases, nonselective beta-blockers, endoscopy, and interventional or surgical therapy should be used for the prevention and treatment of PH complications.
- hypertension, portal /
- diagnosis /
- therapy /
- editorial

HTML全文

参考文献(27)

[1]GARCIA-TSAO G, ABRALDES JG, BERZIGOTTI A, et al.Portal hypertensive bleeding in cirrhosis:Risk stratification, diagnosis, and management:2016 practice guidance by the A-merican Association for the study of liver diseases[J].Hepatology, 2017, 65 (1) :310-335.

[2]de FRANCHIS R.Expanding consensus in portal hypertension:Report of the Baveno VI Consensus Workshop:Stratifying risk and individualizing care for portal hypertension[J].J Hepatol, 2015, 63 (3) :743-752.

[3]Chinese Society of Hepatology, Chinese Medical Association;Chinese Society of Gastroenterology, Chinese Medical Association;Chinese Society of Endoscopy, Chinese Medical Association.Guidelines for the diagnosis and treatment of esophageal and gastric variceal bleeding in cirrhotic portal hypertension[J].J Clin Hepatol, 2016, 32 (2) :203-219. (in Chinese) 中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会内镜学分会.肝硬化门静脉高压食管胃静脉曲张出血防治指南[J].临床肝胆病杂志, 2016, 32 (2) :203-219.

[4]European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Vascular diseases of the liver[J].J Hepatol, 2016, 64 (1) :179-202.

[5]MARTNLLAHM, ALBILLOS A, BAARES R, et al.Vascular diseases of the liver.Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver[J].Gastroenterol Hepatol, 2017, 40 (8) :538-580.

[6]KHANNA R, SARIN SK.Idiopathic portal hypertension and extrahepatic portal venous obstruction[J].Hepatol Int, 2018, 12 (Suppl 1) :148-167.

[7]THOMPSON RJ, TAYLOR MA, MCKIE LD, et al.Sinistral portal hypertension[J].Ulster Med J, 2006, 75 (3) :175-177.

[8]BOSCH J, ABRALDES JG, BERZIGOTTI A, et al.The clinical use of HVPG measurements in chronic liver disease[J].Nat Rev Gastroenterol Hepatol, 2009, 6 (10) :573-582.

[9]BOSCH J, IWAKIRI Y.The portal hypertension syndrome:Etiology, classification, relevance, and animal models[J].Hepatol Int, 2018, 12 (Suppl 1) :1-10.

[10]ZHANG M, ZHUGE YZ, ZOU XP.Application of interventional techniques in patients with unknown etiologic portal hypertension[J].JPrac Hepatol, 2018, 21 (3) :329-331. (in Chinese) 张明, 诸葛宇征, 邹晓平.介入技术在不明原因的门脉高压症诊治中的应用[J].实用肝脏病杂志, 2018, 21 (3) :329-331.

[11]ABRALDES JG, SARLIEVE P, TANDON P.Measurement of portal pressure[J].Clin Liver Dis, 2014, 18 (4) :779-792.

[12]KHANNA R, SARIN SK.Non-cirrhotic portal hypertensiondiagnosis and management[J].J Hepatol, 2014, 60 (2) :421-441.

[13]RAJESH S, MUKUND A, SUREKA B, et al.Non-cirrhotic portal hypertension:An imaging review[J].Abdom Radiol (NY) , 2018, 43 (8) :1991-2010.

[14]SAHIN A, ARTAS H, TUNC N, et al.Hematological indices in portal hypertension:Cirrhosis versus noncirrhotic portal hypertension[J].J Clin Med, 2018, 7 (8) :196.

[15]LIU F, NING Z, LIU Y, et al.Development and validation of a radiomics signature for clinically significant portal hypertension in cirrhosis (CHESS1701) :A prospective multicenter study[J].EBio Medicine, 2018, 36:151-158.

[16]TSENG Y, MA L, LUO T, et al.Non-invasive predictive model for hepatic venous pressure gradient based on a 3-dimensional computed tomography volume rendering technology[J].Exp T-her Med, 2018, 15 (4) :3329-3335.

[17]SHIHA G, IBRAHIM A, HELMY A, et al.Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis:A 2016 update[J].Hepatol Int, 2017, 11 (1) :1-30.

[18]QI X, BERZIGOTTI A, CARDENAS A, et al.Emerging noninvasive approaches for diagnosis and monitoring of portal hypertension[J].Lancet Gastroenterol Hepatol, 2018, 3 (10) :708-719.

[19]ZHANG J, CHEN MK.Progress of diagnosis and treatment of portal hypertension[J].Chin J Gastroenterol Hepatol, 2018, 27 (3) :341-345. (in Chinese) 张静, 陈明锴.门脉高压症的诊断与治疗进展[J].胃肠病学和肝病学杂志, 2018, 27 (3) :341-345.

[20]QI X.Virtual portal pressure gradient from anatomic CT angiography[J].Gut, 2015, 64 (6) :1004-1005.

[21]GIOIA S, NARDELLI S, PASQUALE C, et al.Natural history of patients with non cirrhotic portal hypertension:Comparison with patients with compensated cirrhosis[J].Dig Liver Dis, 2018, 50 (8) :839-844.

[22]Chinese Portal Hypertension Diagnosis and Monitoring Study Group (Chess) ;Minimally Invasive Intervention Collaborative Group, Chinese Society of Gastroenterology;Emergency Intervention Committee, Chinese Society of Interventionalists, et al.Consensus on clinical applictation of hepatic venous pressure gradient in China (2018) [J].J Clin Hepatol, 2018, 34 (12) :2526-2536. (in Chinese) 中国门静脉高压诊断与监测研究组 (CHESS) , 中华医学会消化病学分会微创介入协作组, 中国医师协会介入医师分会急诊介入专业委员会, 等.中国肝静脉压力梯度临床应用专家共识 (2018版) [J].临床肝胆病杂志, 2018, 34 (12) :2526-2536.

[23]CHEN SY, HUANG XQ, CENG XQ.Etiology and diagnosis of portal hypertension[J].J Pract Hepatol, 2018, 21 (3) :321-324. (in Chinese) 陈世耀, 黄晓铨, 曾晓清.门脉高压症的检查选择与病因诊断[J].实用肝脏病杂志, 2018, 21 (3) :321-324.

[24]TRIPATHI D, STANLEY AJ, HAYES PC, et al.UK guidelines on the management of variceal haemorrhage in cirrhotic patients[J].Gut, 2015, 64 (11) :1680-1704.

[25] GARCA-PAGN JC, CACA K, BUREAU C, et al.Early use of TIPS in patients with cirrhosis and variceal bleeding[J].NEngl J Med, 2010, 153 (10) :2370-2379.

[26]SAUERBRUCH T, SCHIERWAGEN R, TREBICKA J.Managing portal hypertension in patients with liver cirrhosis[J].F1000Res, 2018, 7:533.

[27]SCHWABL P, LALEMAN W.Novel treatment options for portal hypertension[J].Gastroenterol Rep, 2017, 5 (2) :90-103.

施引文献

资源附件(0)

访问统计